BIO GREEN MED SLUTI 6%PFD (BGMSP) Financials
Newest figures come from the 10-K for Q2 FY2026, filed Aug 21, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BGMSP SEC filings page.
BIO GREEN MED SLUTI 6%PFD (BGMSP) reported $747K in revenue for fiscal year 2025, up 1637.2% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Development-stage economics persist: financing inflows sit beside operating cash outflows while customer revenue remains immaterial.
In FY2023, reported net income was$22.6M even as operating income was-$25.5M , an unusual divergence between reported earnings and core operations. That accounting reversal did not translate into cash: operating cash flow was-$16.1M , exposing a cash-conversion gap across the reported operating model.
R&D intensity exceeded revenue in both FY2023 and FY2025, keeping the business development-stage rather than sales-scaled; the pattern is investment-led, not volume-led. By FY2025, R&D was
The balance sheet swung from negative equity and a 0.6x current ratio in FY2024 to positive equity and a 4.7x current ratio in FY2025, indicating a materially different financing posture rather than simply better operating performance. That shift coincided with FY2025 financing cash flow of
Financial Health Signals
BIO GREEN MED SLUTI 6%PFD does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
BIO GREEN MED SLUTI 6%PFD passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
BIO GREEN MED SLUTI 6%PFD reported a net loss of $3.0M while operations used $4.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
BIO GREEN MED SLUTI 6%PFD reported an operating loss of $8.4M against $62K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
BIO GREEN MED SLUTI 6%PFD generated $336K in revenue in Q2 2026. Against the prior quarter it is down 54.8%.
BIO GREEN MED SLUTI 6%PFD's EBITDA was -$418K in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. Against the prior quarter it is down 70.6%.
BIO GREEN MED SLUTI 6%PFD reported -$405K in net income in Q2 2026. This represents an increase of 69.3% from the same quarter a year earlier. Against the prior quarter it is down 105.6%.
BIO GREEN MED SLUTI 6%PFD earned -$0.08 per diluted share (EPS) in Q2 2026. Against the prior quarter it is down 100.0%.
Cash & Balance Sheet
BIO GREEN MED SLUTI 6%PFD recorded an outflow of $352K in free cash flow in Q2 2026, representing a cash shortfall after capex. Against the prior quarter it is down 26.2%.
BIO GREEN MED SLUTI 6%PFD held $3.8M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
BIO GREEN MED SLUTI 6%PFD's ROE was -5.7% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 30.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.7 percentage points.
Not reported for Q2 2026.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
BIO GREEN MED SLUTI 6%PFD reported no capital expenditure in Q2 2026. Against the prior quarter it is down 100.0%.
Not reported for Q2 2026.
Not reported for Q2 2026.
BGMSP Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-K | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-K | Q1'2510-K | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $336K | $743K | N/A | $81K+710.0% | N/A | N/A | $0 | $10K-37.5% |
| R&D Expenses | N/A | N/A | N/A | $5K-99.5% | $68K-96.6% | $822K-70.7% | $880K | $950K-81.9% |
| SG&A Expenses | $497K-60.2% | $389K-90.8% | N/A | $1.0M-18.8% | $1.2M-23.1% | $4.2M+166.4% | $948K | $1.2M-23.9% |
| Operating Income | -$418K+66.5% | -$246K+94.2% | N/A | -$992K+54.4% | -$1.2M+65.7% | -$4.2M+3.2% | -$1.8M | -$2.2M+68.2% |
| EBITDA | -$418K | -$245K | N/A | -$992K+54.4% | N/A | N/A | -$1.8M | -$2.2M+68.2% |
| Interest Expense | $9K+350.0% | $9K+50.0% | N/A | $9K+12.5% | $2K+107.1% | $6K+200.0% | $30K | $8K |
| Income Tax | $9K+350.0% | $30K | N/A | N/A | $2K+100.5% | N/A | $1.2M | -$210K+68.6% |
| Net Income | -$405K+69.3% | -$197K-143.2% | N/A | -$988K+49.5% | -$1.3M+59.5% | -$81K+97.3% | -$3.1M | -$2.0M+67.6% |
| EPS (Basic) | -$0.08+91.8% | -$0.04 | -$3.59+74.9% | -$1.31+97.0% | -$0.98+99.4% | $0.00+100.0% | -$14.29 | -$43.80 |
| EPS (Diluted) | -$0.08 | -$0.04 | -$3.59 | -$1.31 | -$0.98 | $0.00 | -$14.29 | -$43.80 |
| Diluted Shares (Avg) | 6M | 5M | N/A | 2M | 1M | 365,231 | N/A | 44,681 |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
BGMSP Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-K | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-K | Q1'2510-K | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $7.9M+78.5% | $7.6M+102.6% | $8.2M+99.9% | $8.2M+51.6% | $4.4M-46.3% | $3.7M-39.4% | $4.1M-53.5% | $5.4M-56.9% |
| Current Assets | $6.0M+36.2% | $5.6M+51.4% | $6.3M+70.3% | $6.4M+31.2% | $4.4M-43.1% | $3.7M-23.2% | $3.7M-50.6% | $4.9M-55.8% |
| Cash & Equivalents | $3.8M-11.3% | $3.3M-3.2% | $3.5M+11.7% | $3.8M+28.7% | $4.3M-28.7% | $3.5M+23.3% | $3.1M-7.1% | $3.0M-49.8% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $972K | $947K | $1.4M | $1.4M | N/A | N/A | N/A | N/A |
| Accounts Receivable | $1.1M | $1.2M | $1.3M | $725K | N/A | N/A | N/A | N/A |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $1.6M | $1.6M | $1.6M | $1.6M | N/A | N/A | N/A | N/A |
| Total Liabilities | $694K-9.9% | $804K+19.6% | $1.3M-78.6% | $1.1M-83.3% | $770K-89.3% | $672K-92.0% | $6.3M-23.5% | $6.4M-22.5% |
| Current Liabilities | $692K-8.9% | $796K+20.1% | $1.3M-78.7% | $1.0M-84.2% | $760K-89.4% | $663K-92.1% | $6.3M-23.2% | $6.4M-22.1% |
| Non-Current Liabilities | $2K-80.0% | $8K-11.1% | $11K | $60K | $10K+100.0% | $9K-57.1% | $0-100.0% | $0-100.0% |
| Total Equity | $7.2M+97.2% | $6.8M+120.8% | $6.8M+414.7% | $7.1M+831.5% | $3.6M+263.5% | $3.1M+238.8% | -$2.2M-458.2% | -$970K-122.6% |
| Retained Earnings | -$455.0M-3.0% | -$454.6M-3.2% | -$454.4M-3.4% | -$444.3M-1.8% | -$441.8M-1.7% | -$440.5M-2.1% | -$439.5M-2.6% | -$436.4M-3.2% |
Not reported in any period shown, so not listed: Long-Term Debt.
BGMSP Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-K | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-K | Q1'2510-K | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$352K+66.7% | -$278K+91.4% | -$33K+97.6% | -$434K+85.8% | -$1.1M+65.8% | -$3.2M-572.3% | -$1.4M+65.3% | -$3.1M+24.0% |
| Depreciation & Amortization | $0 | $1K | $4K+300.0% | $0-100.0% | N/A | N/A | $1K-87.5% | $1K-85.7% |
| Stock-Based Compensation | $1K-85.7% | $1K-99.9% | N/A | $6K-94.4% | $7K-96.3% | $1.7M+720.7% | N/A | $107K-72.6% |
| Capital Expenditures | $0 | $1K | N/A | N/A | N/A | N/A | N/A | $0 |
| Free Cash Flow | -$352K | -$279K | N/A | N/A | N/A | N/A | N/A | -$3.1M+24.0% |
| Investing Cash Flow | $0 | -$1K | N/A | N/A | N/A | N/A | N/A | $0 |
| Financing Cash Flow | $773K-58.9% | $105K-97.1% | -$259K-116.1% | -$3K-200.0% | $1.9M-70.1% | $3.6M+4715.2% | $1.6M+61.5% | -$1K+98.0% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
BGMSP Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-K | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-K | Q1'2510-K | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -124.4% | -33.1% | N/A | -1224.7% | N/A | N/A | N/A | -21770.0% |
| Net Margin | -120.5% | -26.5% | N/A | -1219.8% | N/A | N/A | N/A | -19570.0% |
| Return on Equity | -5.7%+30.6pp | -2.9%-0.3pp | N/A | -13.9% | -36.3%+289.7pp | -2.6% | N/A | N/A |
| Return on Assets | -5.2%+24.8pp | -2.6%-0.4pp | N/A | -12.1%+24.3pp | -29.9%+9.8pp | -2.2%+45.6pp | -74.6% | -36.4%+11.9pp |
| Current Ratio | 8.63+2.9x | 7.06+1.5x | 4.70+4.1x | 6.43+5.7x | 5.77+4.7x | 5.60+5.0x | 0.59-0.3x | 0.77-0.6x |
| Debt-to-Equity | 0.10-0.1x | 0.12-0.1x | 0.20 | 0.15 | 0.21-7.0x | 0.22 | N/A | N/A |
| Asset Turnover | 0.04 | 0.10 | N/A | 0.010.0x | N/A | N/A | 0.00 | 0.000.0x |
| FCF Margin | -104.8% | -37.5% | N/A | N/A | N/A | N/A | N/A | -30670.0% |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Where BIO GREEN MED SLUTI 6%PFD Ranks
Frequently Asked Questions
What is BIO GREEN MED SLUTI 6%PFD's annual revenue?
BIO GREEN MED SLUTI 6%PFD (BGMSP) reported $747K in total revenue for fiscal year 2025. This represents a 1637.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is BIO GREEN MED SLUTI 6%PFD's revenue growing?
BIO GREEN MED SLUTI 6%PFD (BGMSP) revenue grew by 1637.2% year-over-year, from $43K to $747K in fiscal year 2025.
Is BIO GREEN MED SLUTI 6%PFD profitable?
No, BIO GREEN MED SLUTI 6%PFD (BGMSP) reported a net income of -$3.0M in fiscal year 2025.
What is BIO GREEN MED SLUTI 6%PFD's EBITDA?
BIO GREEN MED SLUTI 6%PFD (BGMSP) had EBITDA of -$8.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is BIO GREEN MED SLUTI 6%PFD's return on equity (ROE)?
BIO GREEN MED SLUTI 6%PFD (BGMSP) has a return on equity of -43.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is BIO GREEN MED SLUTI 6%PFD's operating cash flow?
BIO GREEN MED SLUTI 6%PFD (BGMSP) recorded an outflow of $4.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are BIO GREEN MED SLUTI 6%PFD's total assets?
BIO GREEN MED SLUTI 6%PFD (BGMSP) had $8.2M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does BIO GREEN MED SLUTI 6%PFD spend on research and development?
BIO GREEN MED SLUTI 6%PFD (BGMSP) invested $848K in research and development during fiscal year 2025.
What is BIO GREEN MED SLUTI 6%PFD's current ratio?
BIO GREEN MED SLUTI 6%PFD (BGMSP) had a current ratio of 4.70 as of fiscal year 2025, which is generally considered healthy.
What is BIO GREEN MED SLUTI 6%PFD's debt-to-equity ratio?
BIO GREEN MED SLUTI 6%PFD (BGMSP) had a debt-to-equity ratio of 0.20 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is BIO GREEN MED SLUTI 6%PFD's return on assets (ROA)?
BIO GREEN MED SLUTI 6%PFD (BGMSP) had a return on assets of -36.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does BIO GREEN MED SLUTI 6%PFD's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, BIO GREEN MED SLUTI 6%PFD (BGMSP) held $3.5M in cash, cash equivalents and investments, and reported an operating cash outflow of $4.8M over that year. Dividing the one by the other, the reported balance equals about 9 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is BIO GREEN MED SLUTI 6%PFD's Piotroski F-Score?
BIO GREEN MED SLUTI 6%PFD (BGMSP) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are BIO GREEN MED SLUTI 6%PFD's earnings high quality?
BIO GREEN MED SLUTI 6%PFD (BGMSP) reported a net loss of $3.0M while operations used $4.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can BIO GREEN MED SLUTI 6%PFD cover its interest payments?
BIO GREEN MED SLUTI 6%PFD (BGMSP) reported an operating loss of $8.4M against $62K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.